NCT00884325已完成4 期
Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Pruritus VAS Scores at Baseline, Week 2 and Week 4
研究概览
简要总结
It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra. It will be a welcome addition to our treatment armamentarium if a drug such as Xyzal can control pruritus associated with atopic dermatitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient, male or female subjects of any race, at least 18 years of age.
- •Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study. A female is considered of childbearing potential unless she is:
- •postmenopausal for at least 12 months prior to study drug administration;
- •without a uterus and/or both ovaries; or
- •has been surgically sterile for at least 6 months prior to study drug administration.
- •Reliable methods of contraception are:
- •hormonal methods or intrauterine device in use > 90 days prior to study drug administration;
- •barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
- •vasectomized partner. [Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.]
- •Definitive diagnosis of atopic dermatitis as per Rajka-Hanifin criteria.
- •Visual Analog Scale (VAS) pruritus score of 6 cm or more (moderate to severe itching) at baseline.
- •Willing to refrain from other antihistamines and topical steroids and topical immunomodulators for the duration of the study.
- •Able to understand and comply with the requirements of the study and sign Informed Consent/Health Insurance and Portability Accountability Act (HIPAA) Authorization forms.
排除标准
- •Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
- •Requiring oral treatment for their atopic dermatitis apart from oral antihistamines
- •History of hypersensitivity or idiosyncratic reaction to to any component of the test medication , or to cetirizine.
- •Atopic Dermatitis triggered by an unavoidable irritant/allergen.
- •Skin disease/disorder that might interfere with the diagnosis or evaluation of atopic dermatitis (e.g., erythroderma, skin infection on the affected area, etc.)
- •Non-compliance with the proper wash-out periods for prohibited medications.
- •Uncontrolled chronic disease such as diabetes
- •The presence of renal disease with mild, moderate or severe renal impairment
- •Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.
- •Clinically significant alcohol or drug abuse, in the opinion of the Investigator.
- •History of poor cooperation, non-compliance with medical treatment, or unreliability.
- •Participation in an investigational drug study within 30 days of the Baseline Visit.
研究组 & 干预措施
Xyzal
Experimental
干预措施: Levocetirizine dihydrochloride (Xyzal) (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Pruritus VAS Scores at Baseline, Week 2 and Week 4
时间窗: Baseline - Week 2-Week 4
Consented subjects who met inclusion/exclusion criteria were assigned either 5mg levocetirizine dihydrochloride (Xyzal) or placebo to be taken daily each evening for 28 days. Subjects were asked to complete a Visual Analog Scale to measure itch at Baseline, Week 2 and Week 4. The scale is an eleven point scale ranging from 0-10 with 0 indicating no itch to 10 indicating itch that frequently interferes with daily activities.
次要结局
- Dermatology Life Quality Index (DLQI) Questionnaire Scores at Baseline, Week 2 and Week 4(Baseline - Week 2 - Week 4)
研究者
Leon Kircik, M.D.
Principal Investigator
Derm Research, PLLC
研究点 (1)
Loading locations...
相似试验
终止
不适用
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic DermatitisVitamin D DeficiencyAtopic DermatitisAsthmaNCT01234909Medical College of Wisconsin98
招募中
不适用
HYPNOsis in the Management of Atopic Dermatitis in Children and TeenagersDermatitisNCT05611346Centre Hospitalier Universitaire de la Réunion32
招募中
3 期
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.Moderate to Severe Atopic DermatitisNCT06239311medac GmbH277
招募中
不适用
Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and PsoriasisPsoriasisAtopic DermatitisNCT06448689ActiGraph L.L.C90
已完成
不适用
Eczema Reminder and Accountability ProgramAtopic DermatitisEczemaNCT03735459McMaster University21